Postpartum Depression Pipeline Insight 2022: Emerging Drugs, Key Companies, Clinical Trials Updates

DelveInsight's, "Postpartum Depression Pipeline Insights, 2022," report provides comprehensive insights about 2+ companies and 2+ pipeline drugs in Postpartum Depression pipeline landscape. It covers the Postpartum Depression pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

In the Postpartum Depression pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, Postpartum Depression clinical studies, NDA approvals (if any), and product development activities comprising the technology, Postpartum Depression collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Key takeaways from the Postpartum Depression Pipeline Report

• DelveInsight's Postpartum Depression pipeline report depicts a robust space with 2+ active players working to develop 2+ pipeline therapies for Postpartum Depression treatment.
• The leading Postpartum Depression Companies include Sage Therapeutics, Epharmix, Inc., and others.
• Promising Postpartum Depression pipeline therapies in various stages of development include SAGE-547, Brexanolone, Escitalopram, Aripiprazole, WB001, Escitalopram (Lexapro), and others.
• This segment of the Postpartum Depression pipeline report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical, and Discovery.

Recent Developmental Activities in the Postpartum Depression Treatment Landscape

• Sage Therapeutics is conducting a randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of SAGE-217 in the treatment of adults with severe postpartum depression. The purpose of this study is to determine if treatment with SAGE-217 reduces depressive symptoms in females with severe postpartum depression (PPD) as compared to placebo.

Request a sample and discover the recent advances in Postpartum Depression Treatment Drugs @ https://www.delveinsight.com/report-store/postpartum-depression-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Postpartum Depression Overview

The birth of a baby can trigger a jumble of powerful emotions, from excitement and joy to fear and anxiety. Most new moms experience postpartum "baby blues" after childbirth, which commonly include mood swings, crying spells, anxiety and difficulty sleeping. Baby blues typically begin within the first two to three days after delivery, and may last for up to two weeks. But some new moms experience a more severe, long-lasting form of depression known as postpartum depression. Rarely, an extreme mood disorder called postpartum psychosis also may develop after childbirth. Postpartum depression isn't a character flaw or a weakness. Sometimes it's simply a complication of giving birth.

Postpartum Depression Treatment

There are two main treatments for postpartum depression: medication and therapy. Either one can be used alone, but they may be more effective when used together. It's also important to make some healthy choices in daily routine.
• Medication: Antidepressants have a direct effect on the brain. They alter the chemicals that regulate mood. They won't work right away, though. It can take several weeks of taking the medication before the patients notice a difference in mood.
• Therapy: A psychiatrist, psychologist, or other mental health professional can provide counseling. Therapy can help make sense of destructive thoughts and offer strategies for working through them.

Postpartum Depression Emerging Drugs Profile

• Zuranolone: Sage Therapeutics
Postpartum Depression Therapeutics Assessment
There are approx. 2+ key companies which are developing the therapies for Postpartum Depression. The Postpartum Depression companies which have their Postpartum Depression drug candidates in the mid to advanced stage, i.e. phase III include, Sage Therapeutics and others.

Learn more about the novel and emerging Postpartum Depression Ongoing Clinical Trials Analysis @ https://www.delveinsight.com/sample-request/postpartum-depression-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Postpartum Depression Pipeline Report
• Coverage- Global
• Postpartum Depression Companies include Sage Therapeutics, Epharmix, Inc., and others.
• Postpartum Depression pipeline therapies in various stages of development include SAGE-547, Brexanolone, Escitalopram, Aripiprazole, WB001, Escitalopram (Lexapro), and others.
• Postpartum Depression Therapeutics Assessment: Phases, Mechanism of Action, Molecule Type, Route of Administration, Product Type

Table of Content
1. Introduction
2. Postpartum Depression Executive Summary
3. Postpartum Depression: Overview
4. Postpartum Depression Pipeline Therapeutics
5. Postpartum Depression Therapeutic Assessment
6. Postpartum Depression - DelveInsight's Analytical Perspective
7. In-depth Commercial Assessment
8. Postpartum Depression Collaboration Deals
9. Late Stage Products (Phase III)
10. SAGE-217: Sage Therapeutics
11. Pre-clinical and Discovery Stage Products
12. Inactive Products
13. Postpartum Depression Key Companies
14. Postpartum Depression Key Products
15. Postpartum Depression- Unmet Needs
16. Postpartum Depression- Market Drivers and Barriers
17. Postpartum Depression- Future Perspectives and Conclusion
18. Postpartum Depression Analyst Views
19. Postpartum Depression Key Companies
20. Appendix

Key Questions
Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Postpartum Depression drugs?
• How many Postpartum Depression drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Postpartum Depression?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Postpartum Depression therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Postpartum Depression and their status?
• What are the key designations that have been granted to the emerging drugs?

For further information, refer to the detailed Postpartum Depression Treatment Landscape @ https://www.delveinsight.com/sample-request/postpartum-depression-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Contact Us
Yash Bhardwaj
info@delveinsight.com

About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

This release was published on openPR.